Abstract | OBJECTIVE: PATIENTS: A total of 30 non-obese PCOS patients, compared with 20 body mass index matched control subjects, were evaluated. PCOS patients were given spironolactone 100 mg daily in 21-day long intervals followed by a 7-day pause, for 6 months. MEASUREMENTS: RESULTS: Results are expressed as median (25-75th percentile). At baseline, FMD was significantly lower in PCOS patients than in controls: 6.0 (0.0-11.7) vs 10.2 (6.8-15.9) %, P=0.018. This difference disappeared after 6 months of spironolactone treatment, as FMD in PCOS patients significantly increased to 8.3 (5.7-10.3) %, P=0.034, and was no longer different from controls. In PCOS patients, serum androgen levels did not change during treatment, while total and LDL-cholesterol decreased significantly from 4.8 (4.1-5.1) mmol/l to 4.4 (3.9-4.8) mmol/l and from 2.5 (2.1-3.1) to 2.2. (2.1-2.5) mmol/l, P<0.05 and P<0.05 respectively. CONCLUSION:
|
Authors | Katica Bajuk Studen, Miran Sebestjen, Marija Pfeifer, Janez Prezelj |
Journal | European journal of endocrinology
(Eur J Endocrinol)
Vol. 164
Issue 3
Pg. 389-95
(Mar 2011)
ISSN: 1479-683X [Electronic] England |
PMID | 21156647
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Androgen Antagonists
- Androgens
- Lipids
- Lipoproteins, LDL
- Triglycerides
- Spironolactone
- Testosterone
- Androstenedione
- Aldosterone
- Dehydroepiandrosterone Sulfate
- Renin
- Potassium
|
Topics |
- Adult
- Aldosterone
(blood)
- Androgen Antagonists
(pharmacology, therapeutic use)
- Androgens
(blood)
- Androstenedione
(blood)
- Dehydroepiandrosterone Sulfate
(blood)
- Endothelial Cells
(drug effects)
- Female
- Humans
- Lipids
(blood)
- Lipoproteins, LDL
(blood)
- Polycystic Ovary Syndrome
(blood, drug therapy)
- Potassium
(blood)
- Renin
(blood)
- Spironolactone
(pharmacology, therapeutic use)
- Testosterone
(blood)
- Triglycerides
(blood)
- Young Adult
|